MetaCap

EDAP TMS S.A. (FOCL) vs Outset Medical (OM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

EDAP TMS S.A. (FOCL) has outperformed Outset Medical (OM) over the past year, gaining 13.5% versus a loss of 34.5%. Over five years, FOCL leads with a -53.0% price change compared with -99.6% for OM. EDAP TMS S.A. is the larger company by market cap ($123.2 million vs $53.0 million), about 2.3 times the size, while Outset Medical is growing revenue faster (+5.1% vs +1.6%).

EDAP TMS S.A. converts more of its revenue into profit, with a net margin of -41.5% versus -68.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FOCL+13.48%OM-34.50%
+186%+71%-45%
Nov 21, 20251 yearNov 20, 2026
FOCL-51.49%OM-99.62%
+144%+16%-111%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FOCL versus OM key metrics
MetricFOCLOM
Share price$2.61$2.81
Market cap$123.25M$53.03M
1-day change-7.45%-3.44%
YTD return-20.67%-24.26%
1-year return+13.48%-34.50%
5-year return-52.97%-99.61%
EPS (TTM)$-1.35$-3.78
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$70.53M$119.48M
Revenue growth (YoY)+1.63%+5.09%
Net income (latest FY)$-29.25M$-81.65M
Gross margin42.54%39.13%
Operating margin-35.01%-55.83%
Net margin-41.47%-68.34%
52-week high$6.40$6.49
52-week low$2.11$2.77
Distance from 52-week high-59.22%-56.70%
Analyst consensusbuybuy
Avg. price target upside+218.01%+172.95%
Average volume137.30K140.40K
Shares outstanding47.22M18.87M
Employees289310
SectorHealth CareHealth Care
IndustryBiotechnology: Electromedical & Electrotherapeutic ApparatusBiotechnology: Electromedical & Electrotherapeutic Apparatus

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • EDAP TMS S.A. is about 2.3 times larger than Outset Medical by market value ($123.25M vs $53.03M).
  • FOCL has outperformed OM by 48.0 percentage points over the past year.
  • EDAP TMS S.A. is more profitable, keeping -41.5 cents of every revenue dollar as net income versus -68.3 cents for Outset Medical.

About EDAP TMS S.A.

FOCL stock →

EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications.

Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 289 employees

About Outset Medical

OM stock →

Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.

Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 310 employees

FOCL vs OM FAQ

Which is bigger, EDAP TMS S.A. or Outset Medical?

EDAP TMS S.A. (FOCL) is larger, with a market capitalization of $123.25M compared with $53.03M for Outset Medical (OM).

Which stock has performed better over the past year, FOCL or OM?

FOCL returned +13.48% over the past 12 months, compared with -34.50% for OM (price return, excluding dividends). Past performance does not predict future results.

Are EDAP TMS S.A. and Outset Medical in the same industry?

Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.

More comparisons